Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Failure - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Liver Failure - Pipeline Review, H1 2015', provides an overview of the Liver Failure's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Liver Failure Overview 7 Therapeutics Development 8 Pipeline Products for Liver Failure - Overview 8 Pipeline Products for Liver Failure - Comparative Analysis 9 Liver Failure - Therapeutics under Development by Companies 10 Liver Failure - Therapeutics under Investigation by Universities/Institutes 11 Liver Failure - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Liver Failure - Products under Development by Companies 15 Liver Failure - Products under Investigation by Universities/Institutes 16 Liver Failure - Companies Involved in Therapeutics Development 17 Alfact Innovation 17 Conatus Pharmaceuticals Inc. 18 Digna Biotech, S.L. 19 Grifols, S.A. 20 Immune Pharmaceuticals, Ltd. 21 Ventria Bioscience 22 Liver Failure - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 albumin (human) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ALF-5755 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BI-78D3 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 cardiotrophin-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cell Therapy for Liver Failure - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 emricasan - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 F-573 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ImmuneSafe - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Oligonucleotide for Liver Failure - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Recombinant Protein for Liver Failure - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Stem Cell Therapy for Liver Failure - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 VEN-100 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Liver Failure - Recent Pipeline Updates 51 Liver Failure - Dormant Projects 56 Liver Failure - Product Development Milestones 57 Featured News & Press Releases 57 Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 57 Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 59 Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 59 Apr 02, 2013: ALF-5755 phase II completion 60 Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 60 Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 61 May 06, 2011: ALF-5755 phase II extends to germany 62 May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 62 Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 62 Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables Number of Products under Development for Liver Failure, H1 2015 8 Number of Products under Development for Liver Failure - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Comparative Analysis by Unknown Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Liver Failure - Pipeline by Alfact Innovation, H1 2015 17 Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 18 Liver Failure - Pipeline by Digna Biotech, S.L., H1 2015 19 Liver Failure - Pipeline by Grifols, S.A., H1 2015 20 Liver Failure - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 21 Liver Failure - Pipeline by Ventria Bioscience, H1 2015 22 Assessment by Monotherapy Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Liver Failure Therapeutics - Recent Pipeline Updates, H1 2015 51 Liver Failure - Dormant Projects, H1 2015 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
